Cipla Limited
CIPLA
株式のランク
#1809
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
株価
$14.61
最終同期: 2026-10-19
時価総額
$11.81B
変化（1日）
-0.11%
変化（1年）
-21.65%
国
IN
取引 Cipla Limited (CIPLA)
カテゴリー
Healthcare
Cipla Limited（CIPLA）のP/B比率
October 2026 時点のP/B比率 TTM: 3.11
Cipla Limited の最新の財務報告および株価によると、現在のP/B比率（TTM）は 3.11 です。2024 年末時点でのP/B比率は 4.53 でした。
Cipla Limited の P/B 比率の履歴（2004 ～ 2026）
各年末時点のP/B比率
| 年 | P/B比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 3.11 | -16.73% |
| 2025 | 3.74 | -17.41% |
| 2024 | 4.53 | 45.93% |
| 2023 | 3.10 | -21.21% |
| 2022 | 3.94 | 9.87% |
| 2021 | 3.59 | 65.87% |
| 2020 | 2.16 | -23.32% |
| 2019 | 2.82 | -13.48% |
| 2018 | 3.26 | -14.25% |
| 2017 | 3.80 | 6.45% |
| 2016 | 3.57 | -32.58% |
| 2015 | 5.30 | 86.12% |
| 2014 | 2.85 | -16.93% |
| 2013 | 3.43 | 6.81% |
| 2012 | 3.21 | -17.22% |
| 2011 | 3.87 | -14.35% |
| 2010 | 4.52 | 14.98% |
| 2009 | 3.93 | -13.61% |
| 2008 | 4.55 | -19.79% |
| 2007 | 5.68 | -43.30% |
| 2006 | 10.01 | 102.81% |
| 2005 | 4.94 | -11.35% |
| 2004 | 5.57 | 0.00% |
同業他社のP/B比率
| 企業 | P/B比率 | P/B比率の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 61.86% |
IN
|
